Celldex Therapeutics, Inc.
CLDX
$41.95
-$0.66-1.55%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -96.99% | -97.84% | -89.70% | -- | -70.78% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -96.99% | -97.84% | -89.70% | -- | -70.78% |
| Cost of Revenue | 24.63% | 38.75% | 60.49% | 39.03% | 36.56% |
| Gross Profit | -26.29% | -40.58% | -64.35% | -49.58% | -43.77% |
| SG&A Expenses | 26.10% | 5.81% | 16.35% | 6.29% | 13.84% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.86% | 33.13% | 52.57% | 33.08% | 32.31% |
| Operating Income | -26.26% | -34.58% | -55.56% | -41.23% | -37.87% |
| Income Before Tax | -29.86% | -46.27% | -72.68% | -59.17% | -57.92% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -29.86% | -46.27% | -72.68% | -59.17% | -57.92% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -29.86% | -46.27% | -72.68% | -59.17% | -57.92% |
| EBIT | -26.26% | -34.58% | -55.56% | -41.23% | -37.87% |
| EBITDA | -26.57% | -35.09% | -56.38% | -41.79% | -38.37% |
| EPS Basic | -10.77% | -45.87% | -72.33% | -58.86% | -57.03% |
| Normalized Basic EPS | -10.77% | -45.86% | -72.32% | -58.88% | -57.03% |
| EPS Diluted | -10.77% | -45.87% | -72.33% | -58.86% | -57.03% |
| Normalized Diluted EPS | -10.77% | -45.86% | -72.32% | -58.88% | -57.03% |
| Average Basic Shares Outstanding | 17.24% | 0.28% | 0.20% | 0.19% | 0.56% |
| Average Diluted Shares Outstanding | 17.24% | 0.28% | 0.20% | 0.19% | 0.56% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |